Blood disorders including leukemia and lymphoma can be cured with unrelated donor (URD) hematopoietic cell transplantation (HCT) and cord blood transplantation (CBT). Post-transplant complications and mortality may be lowered through comprehensive HLA matching of the stem cell source. KIR-HLA interactions further define transplant outcome. The clinical practice of URD HCT and CBT today has several unmet needs. HLA identity of the URD does not guarantee that the patient will not develop life-threatening post-transplant complications, indicating the presence of undetected MHC region variation. For patients who lack matched URDs, the rules that govern permissible HLA mismatches are needed so as to broaden the availability of HCT to all patients in need. In CBT, the relevance of undetected disparity at HLA-A, B, C, DR, and DQ is unknown. Natural killer (NK)-mediated effects may further modulate transplant risks. Overall, clinical outcome is inferior for patients of non-Caucasian ethnicity. This project has two major goals. First, we will define the clinical importance of MHC residue variation after URD HCT and CBT by measuring the impact of HLA mismatching in non-Caucasian populations, identifying non-permissible HLA mismatches, and novel MHC resident genes. Second, we will define the clinical impact of KIR-HLA interactions, determine the molecular mechanisms underlying donor NK alloreactivity through a systematic evaluation of activating KIRs and haplotypes, and define mechanisms involved for the development of NK alloreactivity. These research questions will address the current roadblocks in URD HCT and CBT and provide novel laboratory-based information that can be translated to clinical practice for all patients of diverse racial background.
(provided by applicant: Even though blood disorders such as leukemia and lymphoma can be cured through transplantation of stem cells from a healthy unrelated donor or cord blood stem cells, patients suffer from life-threatening complications. The risks of complications after transplantation are caused by variation in the genetic code between the patient and the stem cells. This project will find the genes that are causing the complications so that the information may be used to select unrelated donors and cord blood stem cells that lower risks. In this way, patients can be cured of their cancer and live longer healthier lives.
|Boudreau, Jeanette E; Hsu, Katharine C (2018) Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends Immunol 39:222-239|
|Boudreau, Jeanette E; Hsu, Katharine C (2018) Natural killer cell education in human health and disease. Curr Opin Immunol 50:102-111|
|Luduec, Jean-Benoît Le; Kudva, Anupa; Boudreau, Jeanette E et al. (2018) Novel multiplex PCR-SSP method for centromeric KIR allele discrimination. Sci Rep 8:14853|
|Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659|
|Schöne, Bianca; Bergmann, Sabine; Lang, Kathrin et al. (2018) Predicting an HLA-DPB1 expression marker based on standard DPB1 genotyping: Linkage analysis of over 32,000 samples. Hum Immunol 79:20-27|
|El-Jawahri, Areej; LeBlanc, Thomas W; Burns, Linda J et al. (2018) What do transplant physicians think about palliative care? A national survey study. Cancer 124:4556-4566|
|Petersdorf, Effie W; O'hUigin, Colm (2018) The MHC in the Era of Next-Generation Sequencing: Implications for Bridging Structure with Function. Hum Immunol :|
|Petersdorf, Effie W; Stevenson, Philip; Malkki, Mari et al. (2018) Patient HLA Germline Variation and Transplant Survivorship. J Clin Oncol 36:2524-2531|
|Petersdorf, E W (2017) In celebration of Ruggero Ceppellini: HLA in transplantation. HLA 89:71-76|
|Boudreau, Jeanette E; Giglio, Fabio; Gooley, Ted A et al. (2017) KIR3DL1/ HL A-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation. J Clin Oncol 35:2268-2278|
Showing the most recent 10 out of 45 publications